BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol 2007; 13(46): 6231-6235 [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109 [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
3 Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol 2012;138:1845-52. [PMID: 22722713 DOI: 10.1007/s00432-012-1264-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Li J, Jia Y, Gao Y, Chang Z, Han H, Yan J, Qin Y. Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther 2019;12:2577-83. [PMID: 31040700 DOI: 10.2147/OTT.S191736] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
5 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
6 Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. Onco Targets Ther 2015;8:2407-13. [PMID: 26366095 DOI: 10.2147/OTT.S88679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ, Erdoğan B. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019;83:115-22. [PMID: 30374523 DOI: 10.1007/s00280-018-3713-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26:32-37. [PMID: 18498064 DOI: 10.1007/s12032-008-9077-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
9 Beretta GD, Petrelli F, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, Borgonovo K, Barni S. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol. 2013;30:486. [PMID: 23400961 DOI: 10.1007/s12032-013-0486-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang H, Shi J, Wang Q, Li H, Cai K, Hou X, Li T, Zhong Q, Yu D. Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE. Cancer Immunol Immunother 2010;59:239-46. [PMID: 19633845 DOI: 10.1007/s00262-009-0744-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Palazzolo G, Mollica H, Lusi V, Rutigliani M, Di Francesco M, Pereira RC, Filauro M, Paleari L, DeCensi A, Decuzzi P. Modulating the Distant Spreading of Patient-Derived Colorectal Cancer Cells via Aspirin and Metformin. Transl Oncol 2020;13:100760. [PMID: 32247264 DOI: 10.1016/j.tranon.2020.100760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Mitry E, Lièvre A, Bachet J, Rougier P. Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis 2009;24:605-12. [DOI: 10.1007/s00384-009-0672-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]